Navigation Links
One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
Date:9/21/2007

-- When compared to insulin glargine, exenatide offered added benefits of weight loss and improved beta-cell function when used with metformin --

AMSTERDAM, Netherlands, Sept. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced study results comparing treatment of exenatide injection with insulin glargine on beta-cell function, glycemic control and weight in people with type 2 diabetes. Study findings showed one year of exenatide therapy, as compared to insulin glargine, markedly improved different indices of beta-cell function, along with similar glycemic improvement. In addition, patients treated with exenatide lost weight, whereas patients treated with glargine gained weight. These findings were presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Amsterdam, The Netherlands(1).

In this randomized study, 69 people with type 2 diabetes who were treated with exenatide (5 mcg BID for 4 weeks and 10 mcg BID to 20 mcg TID (20 mcg TID is a currently unapproved dosage of the marketed formulation of exenatide, BYETTA(R) (exenatide) injection) for the remainder of the year) or insulin glargine (both with metformin) were compared on measures of beta-cell function, blood sugar control and weight change after one year (52-weeks) of treatment.

In this study, people with type 2 diabetes who used exenatide for one year, compared to those treated with i
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., COLLEGEPARK,Md.,Nov.25/PRNewswire-USNewswire/--...gcream-likefoamthatstopsseverebleeding,wonfirstpri...oftheGlobalSecurityChallenge2009,companyofficialsa...fromaroundtheworld,Remedium,steampitchedtheirinven...nSchoolofBusiness. ,, Remedium( www.remediumtec...
(Date:11/25/2009)..., NEWYORK,Nov.25/PRNewswire/--Reportlinker.comann...catalogue: ,, MammographyEquipment-AGlobalMar...m/p0164330/Mammography-Equipment---A-Global-Market...ncerinindustrializedaswellasdevelopingnationsisapr...et.Globally,escalatingawarenessaboutbreastcancerha...
(Date:11/25/2009)..., CHAPELHILL,N.C.,Nov.25/PRNewswire/--CempraPharm...es,presidentandchiefexecutiveofficer,willpresentat...0a.m.EST,December1,2009,atTheNewYorkPalaceHotelinN...ompany,stwoleadingantibioticclinicalprogramsforthe..., AboutCempraPharmaceuticals ,, Foundedin2...
Breaking Medicine Technology:Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7American Society for Microbiology honors Jo Handelsman 8703 1Dr Erika Says Newsweek 26apos 3Bs Attack on Oprah Ignores the Many Benefits of Her Health Care Advocacy 47696 1Dr Erika Says Newsweek 26apos 3Bs Attack on Oprah Ignores the Many Benefits of Her Health Care Advocacy 47696 2Media Alert 3A July 10 Run Miles for Special Smiles 47691 1Media Alert 3A July 10 Run Miles for Special Smiles 47691 2
..., Inc. Today,Announced the Top Line Results of the...udy with the Compound Desmoteplase , Aachen (Germa...change, Prime Standard: PA8) and its US partner Fo...d topline results of,the DIAS-2 (Desmoteplase In A...oteplase. The Phase III study was designed to,inve...
...A Plans to Initiate,Phase III Studies in Dry Eye i...-FirstCall/ -- ISTA,Pharmaceuticals, Inc. , today ...alysis of the Company,s Phase IIb clinical study o...atment for dry eye,syndrome. Patients in the ecabe...ctive sign of blink rate. In addition, patients in...
Other Medicine Technology:Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 2Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 3Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 4ISTA Pharmaceuticals Announces Positive Preliminary Results from,Ecabet Sodium Phase IIb Study 2ISTA Pharmaceuticals Announces Positive Preliminary Results from,Ecabet Sodium Phase IIb Study 3ISTA Pharmaceuticals Announces Positive Preliminary Results from,Ecabet Sodium Phase IIb Study 4ISTA Pharmaceuticals Announces Positive Preliminary Results from,Ecabet Sodium Phase IIb Study 5
(Date:11/26/2009)...ndfluseasonuponus,it,smoreimportantthanevertoemplo...idillness. ,, "Weneedtobeproactivenotonlytokeep...,resick,"saidEileenFinerty,RN,MS,CIC(certifiedinin...landoccupationalhealthatHospitalforSpecialSurgery(...soneofthelowestinfectionratesofanyhospitalinthecou...
(Date:11/26/2009)... rollercoaster, study finds , , THURSDAY...tor meets the jubilant sports fan. , A new stud... root for the winning team -- enjoy the greatest s...victory was in doubt, producing feelings of worry ...ing weekend as you,re glued to the TV set, watchin...
(Date:11/26/2009)...P.A. is offering free nationwide confidential cons...l pills who have suffered a Deep Vein Thrombosis (...other related cardiac issues or had their Gallblad...-6405 or go to the firm’s website at http:/...luation form. , (PRWEB) N...
(Date:11/25/2009)...MedicalInc.,aleadingmanufacturerofbreastMRIcoilsan...eadingedgeclinicalapplicationsonitsAegis(TM)medica...cietyofNorthAmerica(RSNA)annualmeetinginChicago,No...veragetheuniquehighqualityimagesgeneratedbySentine...magingmodalitiesformulti-parametricassessment. ,...
(Date:11/25/2009)...andPressJoinEfforttoEducate ,, MEMPHIS,Tenn.,N...lBipolarFoundationandtheMedicAlertFoundationreceiv...m,whichisnowbeingwidelyacceptedasapreventivehealth...olarFoundationreceivedaproclamationofendorsementvi...isianaMitchLandrieu.TheNationalBipolarFoundationst...
Breaking Medicine News(10 mins):Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3
...giverlist.com to Find Quality ...list.com, the nation,s online,destination dedicate...hoices, is helping home care agencies keep up with...and franchise,agencies across the nation including...
...ute of Cardiovascular Disease (GICD) and UCSF have...development of the human vascular system, the ext... that allow blood to reach all tissues and organs.... such as heart disease or cancer, that are impacte...
...ub-Zero Medical receives Governor,s 2008 Excellenc...ecognition of success in international sales; Ohio...ee Fisher present award to CSZ Chairman of the Boa...and the leader in the design and development of ad...
...e men in their 40s has had a prostate specific an... young black men are more likely than young white ...ed in the September 15, 2008 issue of CANCER , a ...ecommendations. , Currently, major medical organi...
... complicated process, as any frustrated dieter mig...te the brain,s intricate neurocircuitry and its ro... a clearer picture of the myriad events that lead ... Center (BIDMC) identifies another piece of this c...
...uting factors to hyperthermia, agency warns , ... aging affects the body,s ability to respond to su...or heat-related illnesses such as heat stroke, hea...ted illnesses include: , Age-related changes to t...
Other Medicine News:Health News:Home Care Agencies Staffing Challenge Solved With Caregiverlist.com 2Health News:Gladstone scientists identify single microRNA that controls blood vessel development 2Health News:Gladstone scientists identify single microRNA that controls blood vessel development 3Health News:State of Ohio Recognizes Cincinnati Sub-Zero for Excellence in International Sales 2Health News:State of Ohio Recognizes Cincinnati Sub-Zero for Excellence in International Sales 3Health News:1 in 5 young men has had recent prostate cancer test 2Health News:Scientists identify another piece of the weight-control puzzle 2Health News:More Than Temperature Puts Elderly at Risk in Heat 2
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: